Article Text

Download PDFPDF
CHMP2B mutations are not a common cause of familial or sporadic amyotrophic lateral sclerosis
  1. I P Blair1,2,
  2. C Vance3,
  3. J C Durnall1,
  4. K L Williams1,
  5. A Thoeng1,
  6. C E Shaw3,
  7. G A Nicholson1,2
  1. 1
    Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord Hospital, Sydney, Australia
  2. 2
    Faculty of Medicine, University of Sydney, Australia
  3. 3
    Department of Neurology, King’s College London School of Medicine, London, UK
  1. Dr I P Blair, Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord Hospital NSW 2139, Australia; iblair{at}med.usyd.edu.au

Statistics from Altmetric.com

Approximately 10% of cases of amyotrophic lateral sclerosis (ALS) are familial with the remainder being sporadic. Known ALS genes combined (including superoxide dismutase 1, SOD1) only account for about 20% of familial ALS cases, or around 2% of all ALS cases. Frontotemporal dementia (FTD) is estimated to be associated with between 3% and 22% of cases of ALS and as many as half of ALS cases appear to have frontotemporal impairment (reviewed by Neumann and colleagues1). Families with comorbid ALS and FTD are increasingly being recognised, and linkage analysis has implicated loci on chromosome 9.1 Taken together, this strongly suggests that ALS and FTD share a common pathogenic basis. Indeed, clinical and pathological overlap has been demonstrated for these disorders.

Mutations in CHMP2B have been previously described in familial FTD.2 Recently, CHMP2B mutations were also described in two unrelated cases with ALS phenotypes, each with an apparent family history of ALS spectrum disorders.3

To further investigate the possible association of CHMP2B mutations with ALS, we conducted a mutation screen of cohorts with “classic” ALS, comprising 166 ALS families and 372 cases of sporadic ALS (all familial ALS were negative for the known ALS genes Superoxide dismutase …

View Full Text

Footnotes

  • Funding: This study was supported by the Motor Neurone Disease Research Institute of Australia, as well as grants from the European Union (contract LSHM-CT-2003-503330, APOPIS), and the Middlemass family.

  • Competing interests: None.

  • Ethics approval: The protocols were approved by the human research ethics committees of Concord Hospital and Kings College.

  • Patient consent: Informed consent was obtained for publication of the details in this report.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.